Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy
Raygene Martier, Jolanda M.P. Liefhebber, Ana Garcı́a-Osta, et al.
Molecular Therapy — Nucleic Acids (2019) Vol. 16, pp. 26-37
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Gene therapy for ALS: A review
Defne A. Amado, Beverly L. Davidson
Molecular Therapy (2021) Vol. 29, Iss. 12, pp. 3345-3358
Open Access | Times Cited: 140
Precise genome-editing in human diseases: mechanisms, strategies and applications
Yanjiang Zheng, Yifei Li, Kaiyu Zhou, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 21
CRISPR/Cas9-Mediated Homology-Directed Repair for Precise Gene Editing
Hongyu Liao, Jiahao Wu, Nathan J. VanDusen, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 4, pp. 102344-102344
Open Access | Times Cited: 21
A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS/FTD
Tristan X. McCallister, Colin K.W. Lim, Madhurima Singh, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Francesco Panza, Madia Lozupone, Davide Seripa, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 4, pp. 213-228
Closed Access | Times Cited: 97
Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis
Natalia Nowicka, Jakub Juranek, Judyta K. Juranek, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 11, pp. 2616-2616
Open Access | Times Cited: 92
C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels
Jimmy Beckers, Arun Kumar Tharkeshwar, Philip Van Damme
Autophagy (2021) Vol. 17, Iss. 11, pp. 3306-3322
Open Access | Times Cited: 88
Gene Therapy for ALS—A Perspective
M Cappella, Chiara Ciotti, Mathilde Cohen-Tannoudji, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4388-4388
Open Access | Times Cited: 85
RNA-based pharmacotherapy for tumors: From bench to clinic and back
Xiangping Liang, Dongpei Li, Shuilong Leng, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 109997-109997
Open Access | Times Cited: 81
Artificial miRNAs as therapeutic tools: Challenges and opportunities
Anna Kotowska‐Zimmer, Marianna Pewińska, Marta Olejniczak
Wiley Interdisciplinary Reviews - RNA (2021) Vol. 12, Iss. 4
Closed Access | Times Cited: 60
Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord
Thomas Leth Jensen, Casper R. Gøtzsche, David P.D. Woldbye
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 60
Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Laxmi Kirola, Ashim Mukherjee, Mousumi Mutsuddi
Molecular Neurobiology (2022) Vol. 59, Iss. 9, pp. 5673-5694
Closed Access | Times Cited: 52
Gene Therapy in Amyotrophic Lateral Sclerosis
Ton Fang, Goun Je, Peter Pacut, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 2066-2066
Open Access | Times Cited: 47
CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro
Katharina E. Meijboom, Abbas Abdallah, Nicholas P. Fordham, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 42
The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis
Jinmeng Liu, Fenghua Zhou, Yingjun Guan, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 572-572
Open Access | Times Cited: 39
Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment
Tereza Filipi, Zuzana Heřmanová, Jana Turečková, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 1, pp. 261-261
Open Access | Times Cited: 70
Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease
Michal Izrael, Shalom Guy Slutsky, Michel Revel
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 64
Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Raygene Martier, Pavlina Konstantinova
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 63
Non-coding RNAs in Nervous System Development and Disease
Beatrice Salvatori, Silvia Biscarini, Mariangela Morlando
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 58
C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD?
Elke Braems, Bart Swinnen, Ludo Van Den Bosch
Acta Neuropathologica (2020) Vol. 140, Iss. 5, pp. 625-643
Open Access | Times Cited: 56
Implications of Selective Autophagy Dysfunction for ALS Pathology
Emiliano Vicencio, Sebastián Beltrán, Luis Labrador, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 381-381
Open Access | Times Cited: 53
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xiaojiao Xu, Dingding Shen, Yining Gao, et al.
Translational Neurodegeneration (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 49
The polyG diseases: a new disease entity
Tongling Liufu, Yilei Zheng, Jiaxi Yu, et al.
Acta Neuropathologica Communications (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 29
Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease
Raygene Martier, Marina Sogorb-González, Janice Stricker-Shaver, et al.
Molecular Therapy — Methods & Clinical Development (2019) Vol. 15, pp. 343-358
Open Access | Times Cited: 47
Approaches to Gene Modulation Therapy for ALS
Katharina E. Meijboom, Robert H. Brown
Neurotherapeutics (2022) Vol. 19, Iss. 4, pp. 1159-1179
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top